{"prompt": "['Trial ID: LP0162-1325', 'Date: 14-Aug-2018', 'Version: 4.0', 'Page 99 of 169', 'EASI75 responder imputation', 'Imputation of missing binary EASI75 data at Week 16 will be done using multiple', 'imputations of the underlying 72-point EASI values within the two groups defined according', 'to randomised treatment arm assuming that data is missing at random within each arm.', '1. Intermittent missing values will be imputed in each group using a Markov Chain', 'Monte Carlo method to obtain a monotone missing data pattern and 100 copies of the', 'dataset will be generated (seed=29099725).', '2. An analysis of covariance (ANCOVA) model is fitted to the EASI value at Week 2.', 'The model will include effects of baseline EASI as a covariate, and region, and', 'baseline disease severity (IGA 3 or 4) as factors. The estimated parameters, and their', 'variances, will be used to impute missing EASI values at Week 2. 100 copies of the', 'dataset will be generated (seed=11109925).', '3.', 'For each of the 100 copies of the dataset, missing EASI values at Week 4 will be', 'imputed in the same way as for Week 2. The imputations will be based on the same', 'ANCOVA model with effects of baseline EASI as a covariate, and region, and baseline', 'disease severity (IGA 3 or 4) as factors together with the EASI value at Week 2 as', 'covariate. The estimated parameters, and their variances, will be used to impute', 'missing values at Week 4.', '4. This stepwise procedure will then be repeated sequentially for Week 6, 8, 10, 12, 14,', 'and 16 with the modification that only the EASI values from the preceding two visits', 'will be included as covariates in addition to baseline EASI as a covariate, and region', 'and baseline disease severity as factors. The missing binary EASI75 response at', 'Week 16 will be derived from the corresponding underlying imputed EASI value.', 'Analysis of Week 16 response', 'For each of the 100 complete data sets, the difference in response rates (either the IGA 0/1 or', 'the EASI75) between treatment groups will be analysed using the Cochran-Mantel-Haenszel', 'test stratified by region (North America, Japan, and Europe) and baseline disease severity', '(IGA 3 or 4). The estimates and standard errors from the 100 analyses will be pooled to one', \"estimated treatment difference and associated standard error using Rubin's rule to draw\", 'inference. From these pooled estimates, the 95% CI for the treatment difference will be', 'calculated.', 'Sensitivity analysis for the secondary estimand', 'Rather than assuming that observations are missing at random within each treatment arm, it is', 'assumed that missing data from subjects who discontinue IMP permanently/receive rescue', 'eDoc-00631888 - Version 4.0']['Trial ID: LP0162-1325', 'Date: 14-Aug-2018', 'Version: 4.0', 'Page 100 of 169', 'medication in the tralokinumab arm will resemble missing data from subjects from the', 'placebo arm who do not discontinue IMP permanently/receive rescue medication. The', 'underlying assumption is that the effect of tralokinumab following rescue medication or', 'permanent treatment discontinuation is similar to the effect of placebo. It should be noticed', 'that this assumption is pronouncedly conservative in favour of placebo as it tends to minimise', 'the differences between arms.', 'Imputation of missing data at Week 16 will be done using a pattern mixture model where', 'missing data in the tralokinumab arm as well as the placebo arm will be imputed from', 'observed data in the placebo arm (using a so-called copy-reference approach). With this', 'exemption, the stepwise multiple imputation procedure and subsequent analysis will be', 'conducted in the same way as specified for the primary analysis of the secondary estimand.', '12.3.5.1.3 Tertiary estimand: \"treatment policy\\'', 'The tertiary estimand for the primary endpoints will be:', 'Treatment difference in response rate after 16 weeks between tralokinumab', 'and placebo regardless of rescue medication and treatment discontinuation.', 'The tertiary estimand assesses the average difference in response rates, resulting from', 'initiation of a treatment regimen with tralokinumab and additional rescue medication as', 'compared to a treatment regimen with placebo and additional rescue medication.', 'Primary analysis for the tertiary estimand', 'Data retrieved at Week 16 for subjects who have permanently discontinued treatment prior to', 'Week 16 will be included in the analysis.', 'Imputation of missing data at Week 16 will be done using multiple imputations within', '4 groups defined according to randomised treatment arm and whether or not subjects have', 'permanently discontinued IMP prior to Week 16. Within a given treatment arm, retrieved data', 'from discontinued subjects will be used to impute missing data for other discontinued', 'subjects. Similarly, the available data from not discontinued subjects will be used to impute', 'data for such patients where the Week 16 value is missing.', 'For not discontinued subjects, the stepwise multiple imputations procedure will be conducted', 'in the same way as specified for the primary analysis of the secondary estimand.', 'For discontinued subjects, it is expected that the number of subjects with retrieved data at', 'Week 16 will be too small to facilitate the same imputation model as mentioned above.', 'eDoc-00631888 - Version 4.0']\n\n###\n\n", "completion": "END"}